Finally, we predict that the efficacy of PT for the treatment of PD in vivo may be achieved by promoting endogenous NSCs to directionally differentiate into dopaminergic neurons through regulation of TET1 and FoxA2. The gene discussed is FOXA2; the disease is Parkinson disease.